Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug;47(8):872-7.
doi: 10.1038/ng.3349. Epub 2015 Jun 29.

Mutational Dynamics Between Primary and Relapse Neuroblastomas

Affiliations

Mutational Dynamics Between Primary and Relapse Neuroblastomas

Alexander Schramm et al. Nat Genet. .

Abstract

Neuroblastoma is a malignancy of the developing sympathetic nervous system that is often lethal when relapse occurs. We here used whole-exome sequencing, mRNA expression profiling, array CGH and DNA methylation analysis to characterize 16 paired samples at diagnosis and relapse from individuals with neuroblastoma. The mutational burden significantly increased in relapsing tumors, accompanied by altered mutational signatures and reduced subclonal heterogeneity. Global allele frequencies at relapse indicated clonal mutation selection during disease progression. Promoter methylation patterns were consistent over disease course and were patient specific. Recurrent alterations at relapse included mutations in the putative CHD5 neuroblastoma tumor suppressor, chromosome 9p losses, DOCK8 mutations, inactivating mutations in PTPN14 and a relapse-specific activity pattern for the PTPN14 target YAP. Recurrent new mutations in HRAS, KRAS and genes mediating cell-cell interaction in 13 of 16 relapse tumors indicate disturbances in signaling pathways mediating mesenchymal transition. Our data shed light on genetic alteration frequency, identity and evolution in neuroblastoma.

Similar articles

See all similar articles

Cited by 78 articles

See all "Cited by" articles

References

    1. Nature. 2012 Feb 22;483(7391):589-93 - PubMed
    1. Science. 1984 Jun 8;224(4653):1121-4 - PubMed
    1. Clin Cancer Res. 2009 Mar 15;15(6):2085-90 - PubMed
    1. Nat Genet. 2013 Aug;45(8):933-6 - PubMed
    1. Cell Rep. 2014 Jun 12;7(5):1740-52 - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources

Feedback